Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

OBJECTIVE: Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B (NCT02091375). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or a second placebo‐controlled trial, GWPCAR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Epilepsia
Hlavní autoři: Devinsky, Orrin, Nabbout, Rima, Miller, Ian, Laux, Linda, Zolnowska, Marta, Wright, Stephen, Roberts, Claire
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Full‐length Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379690/
https://ncbi.nlm.nih.gov/pubmed/30582156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/epi.14628
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky